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Abstract: Bacteria belonging to the Vibrionaceae family are widespread in the marine 
environment. Today, 128 species of vibrios are known. Several of them are infamous for 
their pathogenicity or symbiotic relationships. Despite their ability to interact with 
eukaryotes, the vibrios are greatly underexplored for their ability to produce bioactive 
secondary metabolites and studies have been limited to only a few species. Most of the 
compounds isolated from vibrios so far are non-ribosomal peptides or hybrids thereof, with 
examples of N-containing compounds produced independent of nonribosomal peptide 
synthetases (NRPS). Though covering a limited chemical space, vibrios produce 
compounds with attractive biological activities, including antibacterial, anticancer, and 
antivirulence activities. This review highlights some of the most interesting structures from 
this group of bacteria. Many compounds found in vibrios have also been isolated from 
other distantly related bacteria. This cosmopolitan occurrence of metabolites indicates a 
high incidence of horizontal gene transfer, which raises interesting questions concerning 
the ecological function of some of these molecules. This account underlines the pending 
potential for exploring new bacterial sources of bioactive compounds and the challenges 
related to their investigation. 
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1. Introduction 
Marine Vibrionaceae are Gram-negative, rod-shaped γ-proteobacteria that are usually motile and 
possess a chemoheterotrophic metabolism [1]. Members of this family are widespread in the marine 
environment, including estuaries, coastal waters, and sediments [1]. At this writing,   
the family includes seven genera (Figure 1): Allivibrio  (6 species), Enterovibrio (4 species),  
Salinivibrio (6 species), Catenococcus (1 species), Grimontia (1 species), Vibrio (89 species), and  
Photobacterium (21 species) [1,2]. 
Figure 1. Evolutionary relationship of the Vibrionaceae family [3–7]. 
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1.1. Occurrence and Ecological Significance 
Vibrios are particularly abundant on the surface of marine macroorganisms such as corals, fish, 
seagrass, sponges, and zooplankton, where they form commensal, symbiotic, or pathogenic 
associations [1]. Excellent books and reviews have been published on the taxonomy [8], 
ecology [1,9,10], and pathogenesis of vibrios [11–14]. Several species are well studied and serve as 
model systems for understanding symbioses [15,16], interspecies signaling [17], and pathogen 
persistence [11,18]. A particularly famed vibrio is Vibrio fischeri, known for its light organ symbiosis 
with the Hawaiian squid Euprymna scolopes [15]. V. fischeri colonizes the squid light organ and 
provides bioluminescence for the squid to use as countershading in order to evade predators. In return, 
the bacteria gain a protected nutrient environment. The discovery of N-acylhomoserine lactones 
(Figure 2) as quorum sensing signals was first made in V. fischeri and the LuxI/R system of V. fischeri 
is the paradigm of Gram-negative QS systems even though it is not found in all vibrios [18]. In 
V. fischeri, there are three distinct QS signals; 3-oxo-C6-HSL (1), C8-HSL (2), and AI-2 (3). These are 
used to control a regulatory cascade leading to induction of luminescence. Vibrios also use QS to 
control traits such as virulence and biofilm formation [17].  
Figure 2. Structures common quorum sensing molecules from Vibrio sp. 
 
The Vibrionaceae include species that are opportunistic pathogens of humans and marine animals. 
V. vulnificus, V. parahaemolyticus, and V. cholerae are serious human pathogens. V. cholerae probably 
has the greatest impact on human health, causing the acute diarrheal disease cholera that can result in 
epidemics [11]. It is a very persistent bacterium that can survive on a variety of vectors, including 
zooplankton [19] and cyanobacteria [18]. V. parahaemolyticus [20] and V. vulnificus [12] are   
food-borne pathogens associated with the ingestion of raw seafood. V. anguillarum, V. salmonicida, 
and  V. vulnificus are important fish pathogens and are widespread in aquaculture settings, where 
conditions seem to enhance their virulence [1].  
The ability to form biofilms is widespread among vibrios and plays a significant role in the 
pathogenicity of V. cholera [21], V. parahaemolyticus, and V. vulnificus [22],  as well as in the 
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symbiotic colonization by V. fischeri [23,24]. Key proteins include pili, lectins, exopolysaccharides, 
and components involved in the formation of flagella [22]. Though vibrios share a high number of 
regulatory systems of biofilm formation, there are differences that could reflect different niche 
specificity or ecological roles [25]. For example, it appears that vibrios produce species-specific 
exopolysaccharides, the major component of bacterial biofilms, and often have the potential to produce 
more than one type [22].  
High densities of Vibrio and Photobacterium on the surface of zooplankton [26] have in part been 
ascribed to the ability of vibrios to utilize chitin, an N-acetyl D-glucosamine polymer in zooplankton 
exoskeletons, as carbon and nitrogen source [27]. The presence of chitinases and chitinase encoding 
genes has been confirmed for several members of the family [27,28]. Chitin controls several genetic 
and physiological characteristics of vibrios [19] including antagonistic activity [29]. Also, vibrios are 
able to degrade other complex carbohydrates such as fucoidan and laminarin found in algal   
species [29,30]. Thus, this superior nutrient utilization may be one of the reasons for the ubiquitous 
presence of vibrios in the marine environment [31].  
1.2. Genomic Diversity and Phylogeny 
In contrast to most γ-proteobacteria, vibrios possess two circular chromosomes [32,33]. Essential 
functions and housekeeping genes are usually located on the large chromosome ChrI, which is rather 
constant in size (~3 Mb), while the smaller ChrII is flexible in size, ranging between 0.8–2.4 Mb [9].
 
ChrII contains accessory genes related to transcriptional regulation, for example, pathogenicity and 
antimicrobial resistance [9,34]. Genes encoding chitin metabolism and quorum sensing are split 
between the two chromosomes [9]. The ability of vibrios to vary the copy numbers of the two 
chromosomes is suspected to be involved in the adaptation to varying environmental conditions [34]. 
Horizontal gene transfer is involved in the genetic flexibility of vibrios, including transduction   
by phages, plasmid conjugation [35], and so-called “super-integrons” [36,37]. In addition,   
Meibom et al. (2005) [38] showed that vibrios become naturally competent when grown in the 
presence of chitin, allowing uptake of free DNA from the environment. Chitin-induced competence 
has been demonstrated in V. cholera [38], V. vulnificus [39], and V. fischeri [40].  
The high genomic diversity of vibrios can be directly translated into high phenotypic variability [41]. 
This makes it difficult to obtain meaningful groupings of vibrios at genus and species level based on 
isolated phenotypical markers [1]. Also, the 16S rRNA gene is highly conserved, and present in 
serveral alleles, among the Vibrionaceae and not well suited for identification to the species level [41]. 
Attempts to improve the taxonomy include sequencing and comparison of various housekeeping genes, 
including recA, rpoA, toxR, which hold greater sequence variability than 16S [41,42]. Taxonomy of 
vibrios by genetic markers has been supplemented by chemical analyses, including fatty acid methyl 
ester (FAME) profiling, and more recently by whole-cell MALDI-TOF MS [43,44], and LC-UV/MS 
chemical profiling [29,45]. Chemotyping was found to be especially useful at sub-species level, 
identifying differences in antibiotic production [29]. Whole-cell MALDI-TOF MS was able to 
distinguish closely related species like V. parahaemolyticus and V. alginolyticus or V. cholerae and  
V. mimicus scouting potential biomarkers within a 4000–14,000 Da mass range [43]. Closely related 
species (V. coralliilyticus and V. neptunius) could be distinguished based on their secondary metabolite Mar. Drugs 2011, 9 
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production (Figure 3) [45]. Despite intra-species differences [29], the chemical profiles corroborated 
the phylogenetic relationship and clearly showed that production of secondary metabolites in vibrios is 
more than a strain specific trait. 
Figure 3. LC-MS profiles of a V. coralliilyticus (A) and V. neptunius (B), showing 
significant differences in secondary metabolite production. Andrimid (RT 10.02) was only 
found in V. coralliilyticus strains. Figure modified from Wietz et al. (2010) [45]. 
 
2. Natural Product Production by Members of the Vibrionaceae Family 
Considering their widespread presence in the marine environment and their genomic flexibility, 
vibrios are largely underexplored for their proclivity to produce secondary metabolites. So far, a total 
of 93 compounds have been isolated from Vibrionaceae. The majority of these compounds have been 
isolated from only three species; V. parahaemolyticus, V. anguillarum, and V. vulnificus, which is 
likely a reflection of their importance as pathogens. In the following, all metabolites reported   
from Vibrionaceae (Table 1) will be presented and interesting compounds highlighted in an attempt to 
give an overview of the chemical diversity and assess the biosynthetic potential of this group   
of bacteria.  
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Table 1. Bioactive compounds produced by marine Vibrionaceae. Excluded from the list 
are sugars, fatty acids, and small peptides commonly found in marine culturable bacteria. 
Excluded are also compounds from AntiBase 2010 whose presence could not be confirmed 
in any reference referring to Vibrionaceae.  
Bioactivities Name  Compound  class  Source 
Other 
activities 
Ref. 
Antibacterial 
Andrimid (4) Pyrrolidinedione  V. coralliilyticus    [45,46] 
Aqabamycin A (6) Nitro  maleimide  Vibrio sp.  Anticancer [47,48] 
Aqabamycin B (7) 
Aqabamycin C (8) 
Aqabamycin D (9) 
Aqabamycin E (10) Maleimide  oxime 
Aqabamycin E’ (11) 
Aqabamycin F (12) 
Aqabamycin G (13) Nitro  maleimide 
B-4607-C Phenazine  Vibrio sp.    [49] 
Cycloprodigiosin (15) Prodiginine  V. gazogenes   [50] 
3,5-Dibromo-2-(3′,5′-dibromo-
2′-methoxyphenoxy)-phenol 
Diphenyl ether  Vibrio sp.   Antifungal [51,52] 
2,2-Di-(3-indolyl)-3-indolone Indole  V. parahaemolyticus   [53,54] 
Griseoluteic acid  Phenazine  Vibrio sp.    [49] 
Holomycin (5) Pyrrothine  P. halotolerans   [45] 
Indazole-3-carbaldehyde Indazole  Vibrio sp. Anticancer  [47] 
Magnesidin A (16)  Tetramic acid Mg
2+ 
salt 
V. gazogenes  Antialgal [55] 
Moiramide B  Pyrrolidinedione  Vibrio sp.   [56] 
Ngercheumicin A (19) Depsipeptide  Photobacterium sp.   [57] 
Ngercheumicin B (20) 
Ngercheumicin C (21) 
Ngercheumicin D (22) 
Ngercheumicin E (23) 
Pelagiomicin C  Phenazine  Vibrio sp.  Anticancer [49,58,59] 
Prodigiosin (14) Prodiginine  V. psychroerythrus 
V. gazogenes 
V. ruber 
Antiprotozoan 
antifungal 
anticancer 
[60–62] 
Turbomycin Indole  Vibrio sp. 
(V. parahaemolyticus) 
Antifungal [54] 
Unnarmicin A (17) Depsipeptide  Photobacterium sp.  Antifungal [63] 
Unnarmicin C (18) 
Vibrindole A  Indole  V. parahaemolyticus  Antifungal [53] Mar. Drugs 2011, 9 
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Table 1. Cont. 
Bioactivities Name  Compound  class  Source 
Other 
activities 
Ref. 
Siderophore 
Anguibactin (24) Catechol 
hydroxamate 
V. anguillarum  Anticancer [64,65] 
Aerobactin Hydroxamate  Vibrio sp.   [66] 
Amphibactin B  Hydroxamate 
(amphiphilic) 
Vibrio sp.   [67] 
Amphibactin C 
Amphibactin D 
Amphibactin E 
Amphibactin F 
Amphibactin G 
Amphibactin H 
Amphibactin I 
Bis-[3-(2,3-dihydroxy-
benzoylamino)-propyl]-amin 
Catechol  V. fluvialis   [68] 
Bisucaberin (29) Hydroxamate  V. salmonicida  Anticancer [69,70] 
Divanchrobactin Catechol  Vibrio sp.   [65] 
Fluvibactin (28) Catechol 
Hydroxyphenyl-
oxazolone 
V. fluvialis   [66] 
Trivanchrobactin Catechol  Vibrio sp.   [65] 
Vanchrobactin (25) Catechol  V. anguillarum    [71] 
Vibriobactin (27) Catechol 
Hydroxyphenyl-
oxazolone 
V. cholerae   [72] 
Vibrioferrin Carboxylate  V. parahaemolyticus   [73] 
Vulnibactin (26) Catechol 
Hydroxyphenyl-
oxazolone 
V. vulnificus   [74] 
Vulnibactin 2  Vulnibactin 
precursor  Vulnibactin 3 
Anticancer 
Kahalalide F (30) Depsipeptide  V. mediterranei  
(V. shilonii) 
Antibacterial 
antimalarial 
antifungal 
[75] 
Kahalalide H    [76] 
Kahalalide J 
 
  Mar. Drugs 2011, 9 
 
 
1447
Table 1. Cont. 
Bioactivities Name  Compound  class  Source 
Other 
activities 
Ref. 
Quorum 
sensing 
interference 
AI-2 (3) Furanosyl  borate 
diester 
Vibrio  QS [76] 
N-hexanoyl-L-homoserine 
lactone 
Homoserine 
lactone 
V. anguillarum  QS [77] 
N-(3-hydroxybutanoyl)-L-
homoserine lactone 
Homoserine 
lactone 
V. harveyi  QS [78] 
N-(3-hydroxyhexanoyl)-L-
homoserine lactone  
Homoserine 
lactone 
V. anguillarum   QS [79] 
[1-(2′-methylpropoxy)-2-
hydroxy-2-methyl-
propoxy]butane (41) 
  P. angustum  
(V. angustum) 
QS [80] 
N-(3-oxodecanoyl)-L-
homoserine lactone 
Homoserine 
lactone 
V. anguillarum  QS [81] 
N-(3-oxohexanoyl)-L-
homoserine lactone (1) 
Homoserine 
lactone 
V. fischeri 
V. cholerae 
V. harveyi 
V. anguillarum 
QS [17,82] 
N-octanoyl-L-homoserine 
lactone (2) 
Homoserine 
lactone 
V. fischeri  QS [77] 
Solonamide A (32) Depsipeptide  P. halotolerans  QSI Gram pos  [83] 
Solonamide B (33) 
Na channel 
blocker 
Anhydro-tetrodotoxin   Vibrio sp.   [84,85] 
4-epi-tetrodotoxin   Vibrio sp.   [84,85] 
Tetrodonic acid    Vibrio sp.   [85,86] 
Tetrodotoxin (31)   V. harveyi 
V. alginolyticus 
V. fischeri 
 [84,85,87]
Riboflavin 
synthase 
inhibitor 
7-hydroxy-6-methyl-8-(1-D-
ribityl)lumazine 
Pteridine  P. phosphoreum   [88] 
Photolumazine A 
Photolumazine B 
Photolumazine C 
 
  Mar. Drugs 2011, 9 
 
 
1448
Table 1. Cont. 
Bioactivities Name Compound  class  Source 
Other 
activities 
Ref. 
Misc. 
Arundine Indole  V. parahaemolyticus   [54] 
Benzoic acid  Aromatic  Vibrio sp.   [47] 
3,3-Bis-(3-indolyl)butan-2-one Indole  V. parahaemolyticus   [54] 
3,3′-Bisindolylmethane 
1,4-dithiane   Vibrio sp.   [47] 
3-hydroxybenzoic acid  Aromatic  Vibrio sp.   [47] 
4-hydroxycinnamic acid 
p-Hydroxyphenyl-acetamide Aromatic  V. parahaemolyticus   [54] 
Indole-3-carboxaldehyde Indole  V. parahaemolyticus   [53] 
Indole-3-acetic acid  Indole  Vibrio sp.   [89] 
6-methyl-8-D-ribityl-2,4,7-
trioxopteridine 
Pteridine  P. phosphoreum   [90] 
3-nitro-4-hydroxy-benzaldehyde Nitro  aromatic  Vibrio sp.   [47] 
3-nitro-4-hydroxycinnamic acid 
3-nitro-1H-indazole 
Pharacine (43) Terephthalic  ester  V. parahaemolyticus   [54] 
Phenylacetic acid  Aromatic  Vibrio sp.   [47] 
Phenyl-2-bis-indolylmethane Indol 
Photopterin A  Pteridine  P. phosphoreum   [90] 
8-D-ribityl-2,4,7-trioxopteridine 
Trisindoline Indole  V. parahaemolyticus   [54] 
1,1,3-Tris-(3-indolyl)butane 
1,1′,1″-Trisindolyl-methane (42) 
2.1. Compounds with Antibacterial Activity 
Some marine vibrios produce antibacterial compounds [91–93] that are believed to contribute to 
their abundance in surface-associated communities [94]. Long and Azam (2001) [92] studied   
anta-gonistic interactions among pelagic bacteria and found that vibrios produced broad-range 
antibacterial compounds. Similar capabilities have been observed for coral-associated vibrios [95]. 
Yet, none of these compounds were isolated and structurally characterized. The relatively widespread 
production of antibiotics in marine vibrios [45] indicates that antagonistic activity is of ecological 
importance [29].  
Probably the best studied antibiotic produced by vibrios is the hybrid NRPS-PKS peptide antibiotic 
andrimid (4) (Figure 4) [46]. The compound interferes with fatty acid biosynthesis [96] and is effective 
against a wide range of bacteria [97]. Structure-activity studies by Pohlmann et al. (2005) [96] 
revealed that the pyrrolidinedione head was essential for activity, while variations in the fatty acid tail 
were more tolerable. This suggested that these two structural moieties play different roles in   
target binding.  
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Figure 4. Structure of andrimid isolated from Vibrio coralliilyticus. 
 
Andrimid is a cosmopolitan antibiotic found in distantly related bacteria, including a symbiotic 
Enterobacter sp. from the planthopper Nilaparvata lugens [98], Pseudomonas flourescens [99], 
Pantoea agglomerans [100], and Vibrio sp. [45,46]. The andrimid biosynthetic gene cluster was 
conserved in two different producers [101]. Interestingly, the cluster encodes resistance genes [102] as 
well as specific transposases that could be responsible for the diverse occurrence of this   
antibiotic [100,101]. From Vibrio species, the compound was first isolated by Oclarit et al. in 1994 [46], 
and Long et al. (2005) [93] identified andrimid as the compound responsible for the growth inhibition 
of V. cholerae by an unidentified Vibrio strain. Production of andrimid was for the first time linked to 
a specific vibrio species by Wietz et al. (2010) [45] that isolated the compound from the culture broth 
of a V. coralliillyticus strain S2052. Within V. coralliilyticus, the production of andrimid is a marker of 
different chemotypes [29]. Two V. coralliilyticus strains S2052 and S4053 from two distant 
geographical locations produced andrimid [45], while the type strain and a close relative did not [29]. 
Interestingly,  V. coralliilyticus S2052 focused its production of secondary metabolites to the 
production of andrimid when grown on chitin and also increased the yield of the antibiotic [29]. The 
bacterium was capable of producing andrimid in a live chitin model system with Artemia [29]. This 
indicated that andrimid potentially contributes to different niche-specificities of V. coralliilyticus.  
Another example of cosmopolitan antibiotics from Vibrionaceae is the highly potent pyrrothine 
antibiotic, holomycin (5) (Figure 5) isolated from a strain closely related to Photobacterium 
halotolerans  [45]. Prior to this isolation, holomycin had only been isolated from actinomycetes, 
including Streptomyces clavuligerus [103], S. griseus [104], and a marine Streptomyces sp. [105].  
Figure 5. Structure of holomycin isolated from Photobacterium halotolerans. 
 
The NRPS biosynthetic cluster encoding holomycin in S. clavuligerus was recently identified by Li 
and Walsh (2010) [106], and this allows for the comparison of the holomycin clusters in other 
producers, including Photobacterium. Holomycin has a broad spectrum of antibacterial activity against 
pathogenic bacteria such as Staphylococcus aureus, S. pneumoniae, S. epidermis,  Enterococcus 
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faecalis, and Escherichia coli [107]. The mode-of-action in E. coli includes inhibition of RNA chain 
elongation, but holomycin is suspected to act as prodrug rather than a direct inhibitor of the RNA 
polymerase [107]. Holomycin is also strongly inhibitory against several marine strains from the 
Roseobacter-clade,  Pseudoalteromonas, and Vibrio, including pathogens such as V. harveyi,  
V. vulnificus, and V. parahaemolyticus [45], altogether suggesting that holomycin plays a role in 
antagonism in the marine environment. 
Yao and Al-Zereini recently (2010) [47,48] isolated a series of nitrosubstrituted maleimides called 
aqabamycins (6–13) (Figure 6) from a coral-associated Vibrio sp. The analogues had varying 
antibacterial activity against Gram-positive bacteria, including Micrococcus luteus, Bacillus subtilis, 
and B. brevis as well as cytotoxic activity [48]. The aqabamycins represent a unique structural group 
both due to their high degree of nitrosubstitution which is rare in nature [108] and the maleimide 
monoxime present in aqabamycin E/E’ (10–11) and F (12).  
Figure 6. Structures of aqabamycin A–G isolated from coral-associated Vibrio sp. 
 
The red pigment and antibiotic prodigiosin (14) (Figure 7) has been isolated from 
V. psychroerythreus [60], V. gazogenes (originally termed Beneckea gazogenes but later revised) [61], 
and  V. ruber [62]. Additional producers of this compound include Alteromonas rubra/ 
Pseudoalteromonas rubra [109,110], Hahella chejuensis [111], and different Serratia  [112], and 
Streptomyces species [113,114]. Prodigiosin and its cyclized analogue (15) [50,115] have a broad 
range of biological activities, including antimicrobial, antimalarial, immunosuppressive, and 
anticancer [116–118]. Prodiginines have clinical potential in anticancer therapy [118], and prodigiosin 
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is currently in preclinical trials (Aida Pharmaceuticals) for pancreatic cancer [116]. The clinical 
potential as antibiotics is, however, limited due to a low therapeutic window and considerable toxic 
effects [119]. Starič et al. (2010) [120] recently demonstrated that the production of prodiginines in a 
Vibrio sp. isolated from estuaries conferred competitiveness against a Bacillus sp. from the same 
sample, suggesting that prodigiosin might act as a antibiotic in the natural environment. Interestingly, 
the prodigiosin producing V. gazogenes also produced the unique magnesium containing antibiotic, 
magnesidin (16) (Figure 7) [55,121–123].  
Figure 7. Structures of prodigiosins and magnesidin. 
 
Shizuri and co-workers isolated two distinct groups of depsipeptides (Figure 8), the unnarmicins [63] 
and ngercheumicins [57] from a Photobacterium sp. with potent, but narrow-spectrum antibacterial 
effect against strains of Pseudovibrio. The unnarmicin A (17) and C (18) consist of four amino acids 
(L-Phe, L-Leu, D-Phe, L-Leu) and a 3-hydroxyoctanoic and 3-hydroxyhexanoic fatty acid, respectively. 
The ngercheumicins A–E have a depsipeptide macrocycle and either a fatty acid (19–20) or peptide tail 
(21–23). They have been patented for treating infections caused by Pseudovibrio denitrificans, though 
no literature describes pathogenic traits of this bacterium [124].  
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Figure 8. Cyclodepsipeptides isolated from Photobacterium sp. 
 
2.2. Siderophores 
Many vibrios produce siderophores as a strategy to sequester iron in the marine environment, where 
the iron level is extremely low [125,126]. This is necessary to maintain important enzymatic processes 
(with iron as cofactor) and a prerequisite for pathogenicity for many vibrios. It should be mentioned 
that siderophores also may have antibacterial activity but are dealt with in a separate section due to 
their specific metabolic function.  
A great structural diversity has been observed among the siderophores produced by Vibrio species 
(Figure 9). V. anguillarum has at least two different siderophore-mediated systems, namely 
anguibactin (24) [64,127] and vanchrobactin (25) [128]. The non-ribosomal peptide anguibactin 
represents a unique structural class of siderophores with both a catechol and hydroxamate ligand and a 
thiazole core [64]. The biosynthetic genes encoding this compound are found on a 65-kb virulence 
plasmid in some V. anguillarum strains. Knock-out of genes involved in anguibactin production 
attenuated virulence, confirming that anguibactin is a prerequisite for successful host-invasion of this 
bacterium [129]. In contrast, the catechol vanchrobactin is chromosome-encoded, and interestingly, the 
coding genes are silenced in anguibactin producing strains [71,130]. Recently, dimeric and trimeric 
versions of vanchrobactin were isolated from an unidentified Vibrio by Sandy et al. (2010) [65]. Also, 
they found anguibactin to possess cytotoxic activities against P388 murine leukemia cells [65].  
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Vibriobactin (27) [72], vulnibactin (26) [74], and fluvibactin (28) (Figure 9) [68] are unique 
siderophores produced by V. cholerae,  V. vulnificus, and V. fluvialis, respectively. They are all 
catechol hydroxyphenyloxalone siderophores that share a rare norspermidine backbone, giving them a 
propeller-like structure. In vibriobactin and vulnibactin, two of the hydroxybenzoyl moieties are linked 
to the backbone through an L-threonine, forming an oxazoline ring. Fluvibactin only has one oxazoline 
ring, with one hydroxybenzoyl directly linked to the norspermidine terminal. Vibriobactin and 
vulnibactin differ only in the number of hydroxylations, and this high structural similarity enables 
cross-utilization of these two siderophores [74].  
Figure 9. Siderophores isolated from Vibrio sp. 
 
Bisucaberin (29) (Figure 9) [69] is a symmetric cyclic dihydroxamate produced by the fish 
pathogen V. salmonicida [70]. Unlike most other vibrio siderophores [129], bisucaberin is produced 
through an NRPS-independent route [131] where alternating dicarboxylic acids and diamine or amino 
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alcohols are assembled through amide or ester bonds [132]. Bisucaberin was found to be useful in 
combinatorial anticancer therapy by sensitizing tumor cells to macrophage-mediated cytolysis [69,133]. 
Siderophores are used as therapeutic deferration agents to treat iron overload in chronically 
transfused thalassemia patients. A stereochemically modified version of fluvibactin efficiently 
removed iron without increasing microbial growth [134]. It has been suggested that siderophores can 
be used for the development of a new class of “trojan horse” antibiotics [135]. Siderophore-antibiotic 
conjugates exploit the iron transport system of the pathogen to penetrate the bacterial outer membrane, 
increasing the antibacterial activity of the antibiotic [136]. Recently, Bergeron et al. (2009) [137] made 
a conjugate linking antibodies to vulnibactin as a strategy towards a vaccine against V. vulnificus. 
2.3. Compounds with Other Activities 
Another interesting group of compounds produced by a member of the Vibrionaceae  is the 
kahalalides. These cyclic depsipeptides were originally isolated from the herbivorous mollusc 
Elysia refescens and its diet, the green algae Bryopsis sp. In particular, kahalalide F (30) (Figure 10) 
has an attractive spectrum of activities against AIDS-related opportunistic infections and against 
cancer cell lines [138]. Kahalalide F is currently undergoing Phase II clinical trials (PharmaMar) for 
the treatment of prostate, lung, and liver cancer [138] and in patients with severe psoriasis 
(PharmaMar/Marinomed) [139]. Interestingly, Hill and Hamann (2005) [75] found kahalalide F as well 
as two analogues to be produced by a V. mediterranei/shilonii. The finding of a microbial origin for 
this compound allows for the large-scale industrial fermentation of this compound rather than arduous 
organic synthesis.  
Figure 10. Structure of kahalalide F isolated from Vibrio mediterranei/shilonii. 
 
Several vibrios produce the potent neurotoxin tetrodotoxin (TTX) (31) (Figure 11), also known as 
the pufferfish poison [85]. The true origin of TTX has been the subject of much debate [140], 
nonetheless V. harveyi and V. alginolyticus isolated from different species of pufferfish produced the 
toxin as well as several analogues [84]. Also, V. fischeri isolated from the intestines of the xanthid 
crab,  Atergatis floridus produced TTX [87]. Vibrios dominated the intestinal microbiota of the 
pufferfish,  Fugu vermicularis vermicularis [84], suggesting that the toxification is caused by   
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TTX-producing bacteria accumulated through the food web [85]. The role of these compounds to 
vibrio itself is still unclear, though it has been suggested to play a role in regulating sodium 
transport [85]. 
Figure 11. Structure of tetrodotoxin isolated from Vibrio harveyi and Vibrio alginolyticus. 
 
Vibrios produce compounds that interfere with the quorum sensing system of Gram-positive 
bacteria. From a strain related to P. halotolerans two novel depsipeptides (Figure 12), solonamides A 
and B (32–33) that interfere with QS regulated virulence genes in S. aureus were isolated [83]. In 
particular, solonamide B dramatically reduced expression of both hla encoding α-hemolysin  and 
RNAIII, while increasing expression of spa encoding Protein A. This suggested that the depsipeptides 
interfere with agr, the global virulence regulator in S. aureus. High structural similarity of the 
solonamides to the natural autoinducers of the agr system suggested that they might be competitive 
inhibitors.  Interestingly, the solonamides had a pronounced effect on virulence gene expression in 
S. aureus strain USA300, which is the predominant community-acquired MRSA (CA-MRSA) strain in 
the USA [141]. The solonamides strongly resemble the unnarmicins (17–18) found in an unidentified 
Photobacterium sp. (Section 2.3.1) [63]. Thus, it is possible that the unnarmicins also possess   
QSI activity.  
Figure 12. Structures of solonamides isolated from Photobacterium halotolerans   
related strain. 
 
Several small molecules isolated from vibrios induce Gram-negative quorum sensing systems. That 
includes various diketopiperazines (DKP) (Figure 13). For example, cyclo(L-Pro, L-Leu) (34), cyclo(L-Pro, 
L-Val) (35), and cyclo(L-Pro,  L-Tyr) (36), DKPs commonly isolated from vibrios [53], modulated 
LuxR-type protein activity though at higher concentrations than AHLs [142]. It is speculated that these 
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dipeptides represent a new class of naturally occurring QS signals potentially involved in interspecies 
signaling, as DKPs are found in most culturable marine bacteria [143]. However, some DKPs are 
likely to be artifacts generated from media components during work-up procedures [144]. De Nys et al. 
(2001) [80] isolated [1-(2′-methylpropoxy)-2-hydroxy-2-methylpropoxy]-butane (37) (Figure 13) from 
P. angustum (V. angustum) S14 with the ability to mediate expression in two AHL-regulated systems, 
inducing bioluminescence in V. harveyi and the AHL reporter system in Agrobacterium tumefaciens.  
Figure 13. Structures of common diketopiperazines from Vibrio  sp. and   
[1-(2′-methylpropoxy)-2-hydroxy-2-methylpropoxy]-butane. 
 
2.4. Compounds with Unknown Activities 
Vibrios also produce numerous compounds for which no biological activity has been reported so 
far. That includes small-molecule by-products, for example some nitro-substituted compounds such as 
3-nitroindazole and 3-nitro-4-hydroxycinnamic acid [47]. From P. halotolerans S2753, we isolated a 
series of cyclic tetrapeptides (Figure 14); cyclo(L-Val-L-Val-L-Val-L-Val) (38), cyclo(L-Val-L-Leu-L-
Val-L-Leu) (39),  cyclo(L-Val-L-Ile-L-Val-L-Ile) (40), and cyclo(L-Leu-L-Ile-L-Leu-L-Ile) (41) 
(Kjaerullf and Mansson, unpublished data).
  These types of peptides are often found in marine 
culturable bacteria [145–147],
 suggesting that they are storage compounds accumulated during growth 
under excess nutrients.  
Many of compounds isolated from vibrios are suspected to be artifacts generated from media 
components during work-up procedures [54,144,148]. These include several bis- and trisindole 
derivatives from a V. parahaemolyticus strain, Bio249 [54]. An example is 1,1,1-tris (3-indolyl) 
methane (42) (Figure 15) that could easily be formed by simple condensation of indole-3-carbaldehyde 
and indole, both having been isolated from V. parahaemolyticus [54]. From the same 
V. parahaemolyticus strain, the cyclic terephthalic acid ester, pharacine (43) [148] was isolated [54]. 
This was suspected to be an artifact from plastic material contaminants; however, fermentation results 
were reproducible with no contact with plastic. Until biosynthetic studies have been performed, the 
true origin of these molecules remains uncertain. 
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Figure 14. Structures of cyclotetrapeptides isolated from Photobacterium. 
 
 
Figure 15. Structures of 1,1,1-tris (3-indolyl) methane and pharacine, examples of 
potential artefacts from work-up of Vibrio extracts. 
 
3. Conclusion 
The versatility and widespread occurrence of vibrios can be ascribed to different characteristics 
such as their superior nutrient utilization, their excellent biofilm formation, and their genetic 
construction. High genomic flexibility in Vibrionaceae makes this group of bacteria very apt to resist 
various environmental changes, for example through the acquisition of biosynthetic genes linked to the 
production of antibiotics or siderophores. So, rampant horizontal gene transfer occurs in these bacteria. 
As a reflection, most compounds isolated from vibrios have also been found in other types of bacteria, 
in many cases from distantly related taxa [45]. Sometimes the mobile genetic elements are even 
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incorporated in the biosynthetic cluster itself, making it even more prone to gene-exchange. The 
antibiotic andrimid is an example of a compound encoded by such a “nomadic gene cluster” [149].  
Production of secondary metabolites in vibrios has been linked to antagonism, intraspecies 
communication, and pathogenicity. The compounds produced by vibrios are mainly non-ribosomal 
peptides or hybrids hereof, with examples of N-containing compounds produced by NRPS-independent 
pathways. Despite this narrow structural span compared to metabolites produced by other marine 
bacteria, vibrios produce compounds with a broad range of interesting biological activities. For 
example the solonamides, cyclic depsipeptides from P. halotolerans were found to attenuate virulence 
in a CA-MRSA strain [83] and the cyclic depsipeptide kahalalide F from V. medierranei [75] that is 
undergoing Phase II clinical trials for the treatment of prostate, lung, and liver cancer [138].  
Many vibrios have multiple lifestyles, including a planktonic (free swimming), sessile (attached to 
zooplankton or other surfaces), and a pathogenic form [1]. As production of secondary metabolites 
often confers a selective advantage to the producing organism [150], the diverse lifestyles of these 
bacteria are reflected in their metabolic capabilities. There are intraspecies variations in the compounds 
produced, with different chemotypes potentially reflecting niche adaptation. For example, antagonistic 
strains of V. coralliilyticus were found to produce andrimid in high yields, while pathogenic related 
strains did not have the ability to produce the antibiotic [29].  
The cosmopolitan occurrence of several vibrio metabolites raises the question whether there are 
unique Vibrionaceae metabolites. Of the 227 vibrio genomes sequenced so far [2,151], only a fraction 
has been fully assembled [33], mainly pathogenic V. cholerae strains [9], and none have been 
functionally annotated with regard to the presence of biosynthetic clusters. Thus, it is still uncertain 
whether these bacteria represent a novel “hotspot” of secondary metabolites. For the future, it will be 
of utmost interest to extend full-genome sequencing to other vibrios and investigate the prevalence of 
biosynthetic genes linked to secondary metabolism. Also, this will make it possible to compare 
homology of biosynthetic genes between diverse producers of cosmopolitan antibiotics. Overall, this 
will allow insight into the ecological roles of these bacteria and the environmental and physiological 
parameters governing production of their secondary metabolites.  
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